EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Determinants of outcomes and advances in CD19 ‐directed chimeric antigen receptor therapy for B‐cell acute lymphoblastic leukemia

Supriya Gupta iD, Mira Kohorst iD, Hassan B Alkhateeb iD

European Journal of Haematology · 2024

DOI: 10.1111/ejh.14132 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Supriya Gupta und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Burkitt Lymphoma, Lymphoma, B-Cell, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 65 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Relapsed and refractory B‐cell acute lymphoblastic leukemia (B‐ALL) is an aggressive B‐cell neoplasm associated with poor outcomes. Conventional multiagent chemotherapy and bispecific antibody therapy may induce remission; however, relapse rates remain high and overall survival is poor. Chimeric antigen receptor T‐cell (CAR‐T) therapy provides durable, deep complete remission, and long‐term cures in relapsed and refractory B‐ALL. However, with this new treatment modality, 10%–30% of patients do not achieve remission, and over 50% experience relapse after therapy. Currently, there are two approved CD19‐specific CAR‐T cell constructs in B‐ALL, Tisagenlecleucel and Brexucabtagene Autoleucel by the United States Food and Drug Administration, and the European Medicines Agency (EMA). In this review, we discuss patients, disease, and CAR‐T predictors of outcomes in B‐ALL. We describe the two approved CD19‐directed CAR‐T cell products, review the current literature, and discuss factors associated with high risks of therapy failure and future direction in CAR‐T cell therapy for B‐ALL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Burkitt LymphomaLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaReceptors, Chimeric AntigenHumansAntigens, CD19Immunotherapy, AdoptiveReceptors, Antigen, T-CellRecurrence

Stichwörter der Autor:innen

B-acute lymphoblastic leukemiaB-cell aplasiachimeric antigen receptor T-cell therapy

Substanzen

Antigens, CD19Receptors, Antigen, T-CellReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Pediatric Hematology-Oncology, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Supriya Gupta, Mira Kohorst, Hassan B Alkhateeb

Zitieren

APA

Gupta, S., Kohorst, M., & Alkhateeb, H. B. (2024). Determinants of outcomes and advances in CD19 ‐directed chimeric antigen receptor therapy for B‐cell acute lymphoblastic leukemia. European Journal of Haematology. https://doi.org/10.1111/ejh.14132

Vancouver

Gupta S, Kohorst M, Alkhateeb HB. Determinants of outcomes and advances in CD19 ‐directed chimeric antigen receptor therapy for B‐cell acute lymphoblastic leukemia. European Journal of Haematology. 2024. doi:10.1111/ejh.14132

BibTeX
@article{Gupta2024,
  author = {Gupta, Supriya and Kohorst, Mira and Alkhateeb, Hassan B},
  title = {Determinants of outcomes and advances in CD19 ‐directed chimeric antigen receptor therapy for B‐cell acute lymphoblastic leukemia},
  journal = {European Journal of Haematology},
  year = {2024},
  doi = {10.1111/ejh.14132}
}
Kostenlos starten →